
Sign up to save your podcasts
Or
In this special episode on SGLT-2 inhibitors and CKD Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in decreasing progression of chronic kidney disease. This special episide is supported by independent educational grant from AstraZeneca.
For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health
4.5
8585 ratings
In this special episode on SGLT-2 inhibitors and CKD Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in decreasing progression of chronic kidney disease. This special episide is supported by independent educational grant from AstraZeneca.
For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health
128 Listeners
318 Listeners
480 Listeners
691 Listeners
283 Listeners
252 Listeners
3,321 Listeners
91 Listeners
1,094 Listeners
695 Listeners
174 Listeners
512 Listeners
321 Listeners
413 Listeners
363 Listeners